

Supplementary

Table S1 Patients characteristic of 24 NPC patients

Patient name	Patient ID	Gender	Age at diagnosis (yrs)	Induction chemotherapy regimen	Radiotherapy regime	Pathological TNM	Clinical stage	TNB	TMB	TPS		CPS		EB virus (copies/mL)		Response
										Pre	Post	Pre	Post	Pre	Post	
ads	P1	Female	46	DOC + NDP + 5FU	IMRT	T4N1	IVA	23	24.14	2%	10%	2%	12%	<500	800	PR
ccs	P2	Male	54	DOC + NDP + 5FU	IMRT	T4N2	IVA	15	22.47	30%	50%	70%	55%	4250	-	CR
ch	P3	Female	49	DOC + NDP + 5FU	IMRT	T4N1	IVA	46	1.57	10%	-	-	-	500	1350	PR
cxl	P4	Male	46	DOC + NDP + 5FU	IMRT	T4N2	IVA	20	22.76	-	-	5%	-	1600	2250	PR
hjh	P5	Male	52	DOC + DDP + CAP	IMRT	T4N1	IVA	15	17.24	2%	-	7%	-	-	-	CR
jxl	P6	Male	45	DOC + NDP + 5FU	IMRT	T2N3	IVA	19	21.38	5%	-	5%	-	1850	-	PR
lj	P7	Male	41	DOC + NDP + 5FU	IMRT	T3N1	III	6	7.59	-	-	-	-	1350	-	CR
lch	P8	Male	54	DOC + NDP	IMRT	T4N2	IVA	2	2.75	1%	30%	2%	30%	1000	-	NA
myl	P9	Male	52	DOC + NDP + 5FU	IMRT	T3N1	III	89	2.84	-	5%	-	5%	-	-	PR
qgx	P10	Female	45	DOC + NDP + 5FU	IMRT	T3N2	III	55	1.97	5%	-	20%	-	1150	-	CR
sj	P11	Female	30	DOC + NDP	IMRT	T3N0	III	/	/	5%	20%	55%	25%	<500	-	CR
wyl	P12	Female	41	DOC + NDP	IMRT	T4N1	IVA	/	/	1%	20%	2%	40%	-	-	CR
wb	P13	Male	40	DOC + DDP + CAP	IMRT	T4N2	IVA	7	13.11	-	-	5%	2%	3450	<500	PR
wkx	P14	Male	43	DOC + NDP	IMRT	T3N3	IVA	60	3.37	-	-	-	-	-	-	/
wl	P15	Male	51	DOC + NDP + 5FU	IMRT	T3N3	IVA	/	/	-	2%	1%	5%	-	-	CR
xwx	P16	Female	44	DOC + NDP + 5FU	IMRT	T4N2	IVA	/	/	-	50%	1%	50%	-	-	CR
xhf	P17	Male	58	DOC + DDP + 5FU	IMRT	T4N2	IVA	/	/	15%	30%	20%	32%	<500	/	PR
yzc	P18	Male	47	DOC + NDP + CAP	IMRT	T3N3	IVA	/	/	2%	-	3%	-	<500	-	PR
yls	P19	Male	56	GEM + DDP	IMRT	T4N2	IVA	27	35.14	-	-	2%	-	<500	850	SD
zc	P20	Male	48	DOC + NDP + 5FU	IMRT	T3N2	III	/	/	-	10%	2%	10%	/	/	NA
zsq	P21	Male	47	DOC + NDP	IMRT	T1N1	II	/	/	80%	50%	81%	51%	2050	-	CR
zjx	P22	Male	19	DOC + NDP + 5FU	IMRT	T4N2	IVA	/	/	95%	40%	95%	40%	-	-	CR
zqm	P23	Male	64	GEM + DDP	IMRT	T3N2	III	43	41.64	-	-	1%	-	-	-	SD
cyq	P24	Male	55	DOC + NDP + 5FU	IMRT	T3N3	III	3	2.07	5%	5%	6%	6%	1500	-	CR

NPC, nasopharyngeal carcinoma; DOC, Docetaxel; NDP, Nedaplatin; 5FU, fluorouracil; DDP, Cisplatin; CAP, Capsaicin; GEM, Gemcitabine; /, missing; -, negative; CR, complete response; PR, partial response; NR, no response; NA, not available.